Skip to content Skip to sidebar Skip to footer
Subscribe Now
Spotlight Interview_Hector De La Riva
SPOTLIGHT

Reuters Pharma 2025: Post-Conference Talks Featuring Hector De La Riva

Hector De La Riva joins PharmaShots Managing Editor Himanshu Sehgal for a riveting conversation on his recent panel discussion at Reuters Events Pharma 2025. “Reimagine Your 2025 Sales Strategy,” the topic of his panel discussion, examined the ever-evolving commercial landscape and the role of field engagement and customer empowerment in shaping strategic investments. Hector stresses…
April 22, 20250Comments

Read more

Alumis & Acelyrin
News

Alumis and ACELYRIN Revise Merger Agreement, Boosting ACELYRIN Stake

Shots: Alumis and ACELYRIN have amended their 2025 merger agreement, which originally granted ACELYRIN stockholders 0.4274 Alumis shares/share, giving them a 45% stake in the combined company As per the amendment, ACELYRIN stockholders will receive 0.4814 Alumis shares/share, allowing them to own 48% of the combined entity on a fully diluted basis; closing expected in Q2'25…
April 22, 20250Comments

Read more

Gilead
News

Gilead Reports Topline P-III (ASCENT-04/KEYNOTE-D19) Trial Data of Trodelvy Regimen for Previously Untreated Triple-Negative Breast Cancer (TNBC)

Shots: The P-III (ASCENT-04/KEYNOTE-D19) trial assessed Trodelvy (10mg/kg, IV, Day 1 & 8 of 21-day cycle) + Keytruda (200mg, IV, Day 1 of 21-day cycle) vs Keytruda + CT in pts (n=443) with inoperable, locally advanced or metastatic TNBC expressing PD-L1 (CPS ≥ 10) Trial showed improved PFS (1EP); OS (2EP) was immature but showed…
April 22, 20250Comments

Read more

Exact Sciences
News

Exact Sciences launches Oncodetect for Molecular Residual Disease (MRD) Detection

Shots: Exact Sciences has launched Oncodetect to detect MRD across multiple solid tumors, with its efficacy supported by strong clinical validation, incl. ~5yrs. of follow-up data from the Alpha-CORRECT study Addiitonally, clinical & analytical validation studies across multiple solid tumors are underway, supported by strategic partnerships for multi-cancer evidence generation Oncodetect test provides clear “Detected”…
April 22, 20250Comments

Read more

Novocure
News

Novocure Reports CE Mark Approval of Optune Lua for Metastatic NSCLC (mNSCLC)

Shots: Novocure has reported CE Mark approval of Optune Lua for mNSCLC adults progressed on Pt-based regimen based on P-III (LUNAR) trial assessing the treatment vs PD-1/PD-L1 inhibitors/docetaxel alone; launch in Germany is expected in coming wks. Trial showed improved OS (1EP), with an mOS of 13.2 vs 9.9mos. with treatment vs PD-1/PD-L1 inhibitors/docetaxel, 18.5…
April 22, 20250Comments

Read more

Daan Biotherapeutics & GC Cell
News

GC Cell Partners with DAAN Biotherapeutics for Tumor Antigen-Specific Antibody Sequence

Shots: DAAN Biotherapeutics & GC Cell have entered into an exclusive technology transfer agreement for tumor antigen-specific antibody sequence As per the agreement, DAAN has granted GC Cell exclusive rights to use its antibody sequence, which targets a protein highly overexpressed in major solid tumors, for research & development of CAR-T & CAR-NK therapies Financial terms of…
April 21, 20250Comments

Read more

Daiichi Sankyo & Astrazeneca
News

Daiichi Sankyo & AstraZeneca Report Topline P-III (DESTINY-Breast09) Trial Data of Enhertu for HER2+ Metastatic Breast Cancer

Shots: Daiichi Sankyo & AstraZeneca have reported topline P-III (DESTINY-Breast09) trial data on Enhertu (5.4mg/kg) ± pertuzumab vs taxane, trastuzumab & pertuzumab (THP) as a 1L treatment of HER2+ metastatic breast cancer pts (n=1157) Enhertu + pertuzumab showed improved PFS (1EP), with PFS benefit observed across all pre-specified subgroups during interim analysis; OS (2EP) remain immature…
April 21, 20250Comments

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]